» Articles » PMID: 19803001

Pharmacokinetic Studies of Ceftazidime in Serum, Bone, Bile, Tissue Fluid and Peritoneal Fluid

Overview
Date 2009 Oct 7
PMID 19803001
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

After a single iv bolus injection of 2 g ceftazidime, concentrations were measured in serum and urine in volunteers and in serum, bone, bile and tissue fluid in patients. The serum half-life was 171 min in volunteers (n=6, average age 26 years) and 221 min in patients (n=12, average age 58 years). The peripheral volumes of distribution were also different, being 7.81 in volunteers and 11.31 in patients. Urinary recovery from the volunteers averaged 92% of the dose. Bone samples free from blood and taken from the femoral head, the pelvis or the femoral shaft contained an average of 24.1 mg ceftazidime per litre of organic bone at 30 min after injection and 19.7 mg/l at 2 h. Samples of fluid from the periprosthetic space after hip replacement contained 25.6 mg/l at 2 h and were above 8 mg/l at 10 h. Bile concentrations reached 36.4 mg/l at 90 min and were above 8 mg/l for over 8 h. Peritoneal fluid samples contained 27.6 mg/l at 1 h and 8.0 mg/l at 8 h. These concentrations are considered sufficient to treat most aerobic infections associated with surgery.

Citing Articles

MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates.

Zidaru A, Eales B, Wang W, Merlau P, Lasco T, Sofjan A J Glob Antimicrob Resist. 2020; 23:385-387.

PMID: 33166758 PMC: 7770049. DOI: 10.1016/j.jgar.2020.10.014.


Tissue concentrations of third-generation cephalosporins (ceftazidime and ceftriaxone) in lower extremity tissues using a tourniquet.

Papaioannou N, Kalivas L, Kalavritinos J, Tsourvakas S Arch Orthop Trauma Surg. 1994; 113(3):167-9.

PMID: 8054241 DOI: 10.1007/BF00441627.


The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates.

Harding S, Harper P Infection. 1983; 11 Suppl 1:S49-53.

PMID: 6339419 DOI: 10.1007/BF01641107.


Clinical pharmacokinetics of the third generation cephalosporins.

Balant L, Dayer P, Auckenthaler R Clin Pharmacokinet. 1985; 10(2):101-43.

PMID: 3888488 DOI: 10.2165/00003088-198510020-00001.


Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Richards D, Brogden R Drugs. 1985; 29(2):105-61.

PMID: 3884319 DOI: 10.2165/00003495-198529020-00002.